Barriers to accessing GLP-1 medications are beginning to break down as drug manufacturers, insurers, and lawmakers look to expand availability, lower costs, and address continued high demand.

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 502.16% and ...

Eli Lilly partners with telehealth company Ro to distribute discounted Zepbound vials at $399/month, while competitor Novo ...

"Wanted" posters of healthcare CEOs were put up in New York City in the wake of the killing of UnitedHealthcare CEO Brian ...

Telehealth firm Ro has partnered with Eli Lilly And Co (NYSE:LLY) to enhance patient access to Zepbound (tirzepatide) ...

Eli Lilly ( LLY -1.72%) may seem like an expensive stock to invest in right now. It's trading at close to 90 times its ...

Direct-to-consumer health and wellness company Ro will now offer access to lower-priced, single-dose vials of weight loss ...

Eli Lilly is partnering with the Flatiron-based telehealth company Ro to sell a cheaper version of its popular weight-loss ...

"Offering Zepbound single-dose vials…through another platform to LillyDirect will help ensure broader availability of ...

Telehealth company Ro said on Wednesday it will provide access to single-dose vials of Eli Lilly's weight-loss drug Zepbound ...

The partnership between Ro and Eli Lilly (LLY) to streamline access to Lilly’s GLP-1 Zepbound single-dose vials for Ro patients with obesity is ...

While other big pharmas have faltered, Lilly made headway in a Phase 3 trial that could provide a treatment option to replace ...